The objective of this study is to apply advanced diffusion imaging in a two-pronged assessment of renal mass patients: (1) characterization of lesion malignancy and subtype, and (2) prediction of renal function stability or decline following partial nephrectomy.

开始日期2022-12-01

申办/合作机构

NYU Langone Health

[+1]

NCT02450279

/ TerminatedN/AIIT

Scintigraphic Comparison of Lung Deposition With Two Nebulizers During Invasive Mechanical Ventilation

Many devices are available for nebulising drug solution during invasive mechanical ventilation. Vibrating-mesh nebulizers ensure the highest lung deposition output. A recent international survey on aerosol therapy during mechanical ventilation (Ehrmann et al. 2013) reported that jet nebulizers remained the mostly used.
The aim of this study is to compare lung deposition of a radiolabeled administered with both nebulizers during invasive mechanical ventilation by planar scintigraphy.

开始日期2016-03-01

申办/合作机构

Cliniques Universitaires Saint-Luc

NCT02429817

/ CompletedN/AIIT

Tomographic Comparison of Aerosol Lung Distribution With Two Nebulizers Through a High Flow Nasal Cannula

Vibrating-mesh nebulizers ensure currently the best deposition output and are recommended in routine use in intensive care unit. However, jet nebulizers remain the most frequently used nebulizers.
On a bench study, aerosol delivery through a high flow nasal cannula (HFNC) was increased using a vibrating-mesh nebulizer as compared to a jet nebulizer.
Lung distribution of nebulized particles delivered through a HFNC has never been investigated in vivo. The aim of this study was to compare aerosol lung distribution with both nebulizers through a HFNC by SPECT-CT.

开始日期2015-04-01

申办/合作机构

Cliniques Universitaires Saint-Luc

100 项与锝[99mTc]喷替酸盐相关的临床结果

登录后查看更多信息

100 项与锝[99mTc]喷替酸盐相关的转化医学

登录后查看更多信息

100 项与锝[99mTc]喷替酸盐相关的专利（医药）

登录后查看更多信息

11,957

项与锝[99mTc]喷替酸盐相关的文献（医药）

2025-04-01·Sugar Tech

Transforming Biomass Energy Waste into Innovative Fertilizer: Impact of Poultry Litter Incineration Ash-Based Fertilizer on Sugar Beet Nutrition, Yield, and Quality

作者: Altunbay, Gulfem ; Abaci, Abdullah Yasar ; Gunes, Aydin ; Deniz Yagcioglu, Kiymet ; Kadioglu, Yusuf Kagan ; Eser, Ummugulsum ; Taskin, Mehmet Burak ; Tugrul, Murat ; Sahin, Ozge

Abstract: This study aims to apply circular economy principles through waste-to-energy processes to safely dispose of harmful materials, generate sustainable energy, and produce fertilizer.Poultry litter incineration ash (PLA) was acidified and enriched with urea to create a compound fertilizer, UMPLA, with a 4-14-5 compositionAs a new material, mol. structure and functional groups of UMPLA were determined using SEM, XRD and RAMAN techniques.The effectiveness of UMPLA was tested on sugar beet, comparing it to the reference fertilizer (12-30-12) at both full and half-reduced P doses.The results showed that using an equal or half-reduced dose of UMPLA produced root yields equivalent to those achieved with the reference fertilizer.The P and Mg concentrations of the leaves increased to the same extent with both fertilizers compared to the control.However, reduced UMPLA resulted in lower P and Mg concentrations compared to the full dose.While, the fertilizer applications did not significantly affect the Fe and Cu concentrations in the plants, Zn and Mn concentrations decreased.Refined sugar yield (RSY) increased significantly with fertilizer applications compared to the control.Both fertilizers had a similar effect on RSY, and even the reduced UMPLA application produced a RSY comparable to that of the full-dose fertilizers.Neither the reference nor UMPLA treatments had any neg. effects on root K, Na, α-amino N, or dry matter content.UMPLA was as effective as the widely used 12-30-12 fertilizer for sugar beet.These findings suggest that PLA, an increasingly abundant waste, can be effectively used as an alternative fertilizer raw material in plant production

2025-04-01·TOXICOLOGY IN VITRO

DTPA and anti-inflammatory drug associations to alleviate Pu-induced response of macrophages in vitro

Article

作者: Riccobono, Diane ; Bourgois, Alexandra ; François, Sabine ; Van der Meeren, Anne ; Le Gallic, Clélia ; Cosler, Guillaume

Internal contamination by inhalation of plutonium poorly soluble compounds leads to their long time retention in alveolar macrophages inducing delayed pathology development. As previous studies highlighted co-localization of retained Pu and inflammatory lesions, this study was designed to assess the combined effect of the reference treatment (DTPA) and anti-inflammatory drugs on Pu-induced early response of macrophages in vitro. Pu colloids, mimicking poorly soluble Pu, were characterized using filtration and solid-state nuclear track detectors CR39. Their bioavailability was determined using a biphasic acellular model. Treatment effects on Pu dissolution and release as well as on Pu-induced pro-inflammatory response were assessed over 7 days on macrophage-like cells. DTPA treatment, associated or not with anti-inflammatory drug, increased Pu dissolution and release from contaminated THP-1 differentiated cells after 7 days. Significant decreases in Pu-induced IL-8 and MCP-1 secretions were also observed with anti-inflammatory treatment associated or not with DTPA. This study highlighted the ability of DTPA to partially dissolve a poorly soluble form of Pu as well as the ability of anti-inflammatory drugs to modulate Pu-induced pro-inflammatory response in macrophage-like cells. These treatments seem a promising strategy to improve the clinical management of Pu pulmonary contaminations and to limit delayed pulmonary pathology occurrence.

2025-03-01·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Single-cell RNA sequencing and machine learning provide candidate drugs against drug-tolerant persister cells in colorectal cancer

Article

作者: Yao, Ryoji ; Suzuki, Takashi ; Nojima, Yosui

Drug resistance often stems from drug-tolerant persister (DTP) cells in cancer. These cells arise from various lineages and exhibit complex dynamics. However, effectively targeting DTP cells remains challenging. We used single-cell RNA sequencing (scRNA-Seq) data and machine learning (ML) models to identify DTP cells in patient-derived organoids (PDOs) and computationally screened candidate drugs targeting these cells in familial adenomatous polyposis (FAP), associated with a high risk of colorectal cancer. Three PDOs (benign and malignant tumor organoids and a normal organoid) were evaluated using scRNA-Seq. ML models constructed based on public scRNA-Seq data classified DTP versus non-DTP cells. Candidate drugs for DTP cells in a malignant tumor organoid were identified from public drug sensitivity data. From FAP scRNA-Seq data, a specific TC1 cell cluster in tumor organoids was identified. The ML model identified up to 36 % of TC1 cells as DTP cells, a higher proportion than those for other clusters. A viability assay using a malignant tumor organoid demonstrated that YM-155 and THZ2 exert synergistic effects with trametinib. The constructed ML model is effective for DTP cell identification based on scRNA-Seq data for FAP and provides candidate treatments. This approach may improve DTP cell targeting in the treatment of colorectal and other cancers.

项与锝[99mTc]喷替酸盐相关的新闻（医药）

2024-09-29

·药事纵横

生物制剂中“明星”表面活性剂——吐温80

介绍：聚山梨酯（吐温，PS）是一类两亲性非离子表面活性剂家族，其中，聚山梨酸酯80（吐温80）是生物药物制剂中使用最广泛的“明星”表面活性剂，可防止蛋白质在储存、运输条件变性、聚集、表面吸附以及絮凝作用。吐温80是一种混合物，主要成分是聚氧乙烯脱水山梨糖醇单油酸酯。作为常用的药物辅料，市售注射用吐温80主要有MC（多药典级）和CP（中国药典级）两种级别，其主要差异在油酸含量上，见表1。其中，CP级别常用供应商日油和南京威尔，MC级别有JT、Sigma和禾大等。吐温80可以通过氧化和水解途径降解，见图1，其中水解反应是化学诱导的或酶催化的，氧化反应一般由化学诱导。吐温80作为生物制剂的一种保护剂辅料使用，但也可能影响蛋白质制剂的质量，从而对功效、安全性和稳定性起到不利作用。目前，药品监管部门对吐温80的控制要求越来越严格。图1 吐温80的主要降解途径有很多学者对吐温80进行了大量研究，下面从吐温80的优缺点、含量测定方法、以及面临挑战几个方面进行介绍。吐温80的优点： PS80是生物制剂中最常用的表面活性剂，在大多数商业治疗性蛋白质制剂中用作蛋白质稳定剂。这是由于以下因素： 1）生物相容性高； 2）低毒性； 3）有效的蛋白质稳定作用。即使在低浓度下（生物制剂中常用浓度为0.1-1.0mg/ml），它们也提供了足够的蛋白质稳定性。这是由于PS80的亲水亲脂平衡（HLB）值高和临界胶束浓度（CMC）低，PS80的CMC仅为1.4*10-2g/L。蛋白质具有天然的不稳定性，易受到外部条件的影响，如温度、震荡、剪切力、缓冲体系及离子强度等，甚至自身的蛋白浓度或纯度的改变。其中，所有蛋白质变性降解的问题中，聚集的问题尤为严重。下游的制剂开发中常常使用吐温80作为蛋白的保护剂。聚山梨酯稳定蛋白质的机理，通常认为界面竞争和表面活性剂-蛋白质复合这两种主要机理。吐温80主要通过界面竞争作用来稳定蛋白质，吐温80的表面活性比蛋白质（即单克隆抗体（mAbs））高很多，因此，吐温80可以竞争性地占据界面位置，抑制蛋白质吸附到气液交界面，进而减少与空气接触造成的氧化或聚集，也有效防止蛋白质在制造过程、样品处理和存储中在界面处展开。吐温80还可以通过与蛋白质直接相互作用，增加蛋白质的胶体稳定性。抗体可能会通过其分子间输水作用形成聚集体。吐温80可通过与蛋白质表面上的疏水相互作用，从而防止蛋白质聚集甚至颗粒的产生。吐温80的缺点：前面提到吐温80其实是一种混合物，市售的预期结构聚氧乙烯脱水山梨糖醇单油酸酯）仅占吐温80总量的20％。如图2所示，异质性主要来来源与工艺相关的副产物杂质，其中不仅含有单酯（预期结构），还含有二酯、多酯，甚至未成酯的脂肪酸链。此外，前面还提到（见图1），吐温80可以发生水解反应及氧化反应导致降解，产生脂肪酸链及氧化物，以上导致对吐温80的表征成为了难点。图2 吐温80主要的化学结构吐温80的表征：吐温80的结构缺乏强发色团，无法直接检测到容易获得的紫外可见光及荧光。目前，很多研究学者已经开发了多种表征方法来控制吐温80的不同性质，表2总结了几种常见含量检测方法的原理及优缺点。然而，由于不同亚种（如未酯化、单酯、多酯）及降解产物（如水解、氧化）对总吐温80含量结果的贡献值存在显著差异，因此用不同原理方法测定的吐温80含量显示出明显的差异。此外，还采用MS或CAD（其中主要应用色谱与MS联合应用）来分析主要吐温80亚种的组成及降解物，例如小的有机分子，游离脂肪酸等，研究解聚山梨酯降解途径。药典方法、HPLC-ELSD/CAD方法对水解产物较为敏感，HPLC-FMA也可测出样品水解，然而测定吐温80氧化方面上，FMA方法更胜一筹，综合来看，HPLC-FMA方法更适用于PS80含量的检测。截止目前为止，吐温80的表征方法层出不穷，但具有各自方法的优点及弊端，其仍然是一项分析挑战，必要时可采取多种检测方式共同评价。面临的挑战：吐温80的水解也就是酯的水解，反应生成的游离脂肪酸链可形成聚集甚至可见颗粒，并且可能与蛋白结合形成脂肪酸-蛋白复合物。在典型的蛋白质制剂pH（4-7）下，吐温80的水解受到限制。有文献表明，酶诱导的吐温80水解是影响产品质量的可见和亚可见颗粒形成的主要原因，实际生产中上游工艺带来的Hcp脂肪酶是催化PS80水解的一个重要因素，其具有与目标蛋白相似的理化性质，因此很难完全去除。即使优化纯化工艺去除Hcp，但远低于检测限的极少量Hcp（ppm级别）也可催化PS80的水解。吐温80可能被光照、温度，过氧化物、氧气或痕量金属离子等影响因素氧化，氧化位置常见脂肪酸链双键、母核的醚键和部分酯键，降解产物有自由基、过氧化物、游离脂肪酸、短链烷烃、醛、酮、酸等。而生成的过氧化物可能继而引起蛋白质氧化。泊洛沙姆188（P188）是另一种在蛋白质制剂中用作蛋白质稳定剂的赋形剂，尽管不如吐温80使用广泛。P188因不具备酯键，不会有发生水解的风险，主要通过氧化形式在溶液中降解，形成氧化的聚氧乙烯（POE）和聚环氧丙烷（PPO）。但P188在上市品种中应用局限，可能存在长期放置过程中潜在风险。因此，推荐使用一些手段减少吐温对蛋白质的负面影响，如2-8℃低温储存、充氮、避光保护；通过上游工艺优化降低Hcp；加入抗氧化剂、金属络合剂等。其中抗氧化剂如甲硫氨酸、赖氨酸、色氨酸等，金属络合剂如EDTA、DTPA等。参考文献： [1] Characterization of Polysorbate 80 by Liquid Chromatography Mass Spectrometry to Understand Its Susceptibility to Degradation and Its Oxidative Degradation Pathway Journal of Pharmaceutical Sciences 111 (2022) 323−334; [2] Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability Mol. Pharmaceutics 2020, 17, 2345−2353; [3] Degradation of polysorbates 20 and 80 catalysed by histidine chloride buffer European Journal of Pharmaceutics and Biopharmaceutics 154 (2020) 236–245. 药事纵横投稿须知：稿费已上调，欢迎投稿

2024-06-11

·PRNewswire

Global Anti-Radiation Drugs Market to Register Incremental Growth at a CAGR of ~9% by 2030 | DelveInsight

The rise in demand for anti-radiation drugs is mainly driven by several factors. These include the growing occurrence of side effects linked to cancer screening methods, heightened risks of exposure to radiological or nuclear emergencies, and the increasing focus of nuclear-capable nations on safeguarding against radiation. These trends are expected to fuel the expansion of the anti-radiation drugs market from 2024 to 2030. LAS VEGAS, June 11, 2024 /PRNewswire/ -- DelveInsight's Anti-Radiation Drugs Market Insights report provides the current and forecast market analysis, individual leading anti-radiation drugs companies' market shares, challenges, anti-radiation drugs market drivers, barriers, trends, and key market anti-radiation drugs companies in the market. Key Takeaways from the Anti-Radiation Drugs Market Report As per DelveInsight estimates, North America is anticipated to dominate the global anti-radiation drugs market during the forecast period. In the compound type segment of the anti-radiation drugs market, the Potassium iodide sub-category had a significant revenue share in the year 2023. This can be ascribed to the various characteristics and advantages associated with potassium iodide. Notable anti-radiation drugs companies such as Novartis AG, Anbex Inc., Amgen Inc., Myelo Therapeutics, Arco Pharmaceuticals LLC, BTG International Inc., Cellphire Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Chrysalis BioTherapeutics Inc., Pluri Inc., Partner Therapeutics, HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG., RxBio Inc., Coherus Biosciences, Onconova Therapeutics, Jubilant Life Sciences, Soligenix Inc., and several others, are currently operating in the anti-radiation drugs market. In September 2023, the U.S. Department of Defense awarded Edina-based Humanetics a USD 20 million contract to develop a pill that prevents radiation damage in military members and first responders affected by events such as nuclear accidents, warfare, and dirty bombs. In May 2023, the first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body, testing the safety, tolerability, and processing in the body of escalating doses of the investigational drug product HOPO 14-1 was initiated in healthy adults. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, was funding the Phase 1 trial, which was sponsored and conducted by SRI International of Menlo Park, California. In March 2022, Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body. These patients have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy). To read more about the latest highlights related to the anti-radiation drugs market, get a snapshot of the key highlights entailed in the Global Anti-Radiation Drugs Market Report Anti-Radiation Drugs Overview Anti-radiation drugs are pharmaceutical compounds designed to mitigate the damaging effects of radiation exposure on the human body. These drugs work by either scavenging free radicals generated by radiation or by enhancing the repair mechanisms of cells damaged by radiation. One class of anti-radiation drugs includes radioprotectors, which are administered before radiation exposure to prevent or reduce its harmful effects. Another class, known as radiomitigators, is given after exposure to alleviate the severity of radiation-induced damage. These drugs hold significant promise in scenarios such as nuclear accidents, medical radiation therapy, and space travel, where the risk of radiation exposure is a concern. Research into anti-radiation drugs is ongoing, with scientists continually striving to improve their efficacy and minimize side effects. Some compounds under investigation show potential not only in protecting against acute radiation sickness but also in mitigating long-term effects such as cancer development. As our understanding of radiation biology advances, coupled with advancements in drug development technologies, the prospects for more effective and accessible anti-radiation drugs continue to brighten, offering hope for safer environments in radiation-prone situations. Anti-Radiation Drugs Market Insights In 2023, North America dominated the anti-radiation drugs market, primarily due to several factors contributing to growth. These include a substantial patient population afflicted with various illnesses like cancer, increasing numbers of diagnostic procedures, and governmental initiatives aimed at public health in the region. This trend is expected to continue from 2024 to 2030. The prevalence of cancer in the United States, for example, drives a significant demand for anti-radiation drugs. Statistics from the American Cancer Society projected around 2 million new cancer cases in the United States in 2024, leading to heightened demand for these drugs to support cancer diagnostic procedures. Additionally, the US benefits from a strong focus on clinical research and the presence of leading pharmaceutical companies, further bolstering the market for anti-radiation drugs. Moreover, in 2022, the US Department of Health and Human Services (HHS) allocated USD 290 million for the purchase of Nplate, a drug produced by Amgen USA Inc., intended to treat radiation sickness in the event of a nuclear emergency. This investment reflects ongoing efforts to enhance preparedness for radiological and nuclear emergencies and underscores the commitment to saving lives in such scenarios. To know more about why North America is leading the market growth in the anti-radiation drugs market, get a snapshot of the Anti-Radiation Drugs Market Outlook Anti-Radiation Drugs Market Dynamics The market dynamics of anti-radiation drugs are driven by a complex interplay of factors ranging from technological advancements to geopolitical events and regulatory frameworks. One of the primary drivers is the increasing threat of radiation exposure from various sources such as nuclear accidents, medical procedures, and potential radiological terrorism. This heightened awareness has propelled research and development efforts to create effective anti-radiation drugs that can mitigate the harmful effects of radiation exposure. Moreover, the growing prevalence of cancer and the widespread use of radiation therapy as a treatment modality has further fueled the demand for anti-radiation drugs. As more individuals undergo radiation-based treatments, there is a parallel need for medications that can protect healthy tissues and organs from the damaging effects of ionizing radiation. The competitive landscape of the anti-radiation drugs market is characterized by both established pharmaceutical companies and innovative startups vying for market share. Established players often leverage their resources and expertise to develop and commercialize new anti-radiation drugs, while startups focus on disruptive technologies and novel approaches to address unmet needs in radiation protection. Government initiatives and regulatory frameworks also play a crucial role in shaping the market dynamics of anti-radiation drugs. Regulatory agencies set standards for safety, efficacy, and quality assurance, which impact the development, approval, and commercialization of these medications. Additionally, government investments in research and development, as well as funding for procurement and stockpiling of anti-radiation drugs for emergency preparedness, influence market dynamics. Overall, the anti-radiation drugs market is characterized by a dynamic landscape driven by technological innovation, healthcare trends, regulatory factors, and geopolitical considerations. As the threat of radiation exposure continues to evolve, so too will the demand for effective anti-radiation drugs, driving further growth and innovation in this important sector of the pharmaceutical industry. Get a sneak peek at the anti-radiation drugs market dynamics @ Anti-Radiation Drugs Market Dynamics Analysis Anti-Radiation Drugs Market Assessment Anti-Radiation Drugs Market Segmentation Anti-Radiation Drugs Market Segmentation By Compound: Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Colony Stimulating Factors, and Others Anti-Radiation Drugs Market Segmentation By Indication: Acute Radiation Syndrome, Cancer Treatment, and Others Anti-Radiation Drugs Market Segmentation By Radiation Type: Ionizing Radiations and Non-Ionizing Radiations Anti-Radiation Drugs Market Segmentation By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others Anti-Radiation Drugs Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the anti-radiation drugs market are set to emerge as the trendsetter explore @ Anti-Radiation Drugs Companies Table of Contents Interested in knowing the anti-radiation drugs market by 2030? Click to get a snapshot of the Anti-Radiation Drugs Market Trends Related Reports Cancer Biomarkers Market Cancer Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer biomarkers companies, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., among others. Cancer Therapy Market Cancer Therapy Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer therapy companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd., among others. Oncology Drugs Market Oncology Drugs Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key oncology drugs companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, BeiGene, among others. Liquid Biopsy in Cancer Diagnostics Market Liquid Biopsy in Cancer Diagnostics Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key liquid biopsy in cancer diagnostics companies, including Myriad Genetics Inc., Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

放射疗法

2022-12-24

·药通社

生物制剂中“明星”表面活性剂——吐温80

介绍：聚山梨酯（吐温，PS）是一类两亲性非离子表面活性剂家族，其中，聚山梨酸酯80（吐温80）是生物药物制剂中使用最广泛的“明星”表面活性剂，可防止蛋白质在储存、运输条件变性、聚集、表面吸附以及絮凝作用。吐温80是一种混合物，主要成分是聚氧乙烯脱水山梨糖醇单油酸酯。作为常用的药物辅料，市售注射用吐温80主要有MC（多药典级）和CP（中国药典级）两种级别，其主要差异在油酸含量上，见表1。其中，CP级别常用供应商日油和南京威尔，MC级别有JT、Sigma和禾大等。吐温80可以通过氧化和水解途径降解，见图1，其中水解反应是化学诱导的或酶催化的，氧化反应一般由化学诱导。吐温80作为生物制剂的一种保护剂辅料使用，但也可能影响蛋白质制剂的质量，从而对功效、安全性和稳定性起到不利作用。目前，药品监管部门对吐温80的控制要求越来越严格。图1 吐温80的主要降解途径有很多学者对吐温80进行了大量研究，下面从吐温80的优缺点、含量测定方法、以及面临挑战几个方面进行介绍。吐温80的优点：PS80是生物制剂中最常用的表面活性剂，在大多数商业治疗性蛋白质制剂中用作蛋白质稳定剂。这是由于以下因素：1）生物相容性高；2）低毒性；3）有效的蛋白质稳定作用。即使在低浓度下（生物制剂中常用浓度为0.1-1.0mg/ml），它们也提供了足够的蛋白质稳定性。这是由于PS80的亲水亲脂平衡（HLB）值高和临界胶束浓度（CMC）低，PS80的CMC仅为1.4*10-2g/L。蛋白质具有天然的不稳定性，易受到外部条件的影响，如温度、震荡、剪切力、缓冲体系及离子强度等，甚至自身的蛋白浓度或纯度的改变。其中，所有蛋白质变性降解的问题中，聚集的问题尤为严重。下游的制剂开发中常常使用吐温80作为蛋白的保护剂。聚山梨酯稳定蛋白质的机理，通常认为界面竞争和表面活性剂-蛋白质复合这两种主要机理。吐温80主要通过界面竞争作用来稳定蛋白质，吐温80的表面活性比蛋白质（即单克隆抗体（mAbs））高很多，因此，吐温80可以竞争性地占据界面位置，抑制蛋白质吸附到气液交界面，进而减少与空气接触造成的氧化或聚集，也有效防止蛋白质在制造过程、样品处理和存储中在界面处展开。吐温80还可以通过与蛋白质直接相互作用，增加蛋白质的胶体稳定性。抗体可能会通过其分子间输水作用形成聚集体。吐温80可通过与蛋白质表面上的疏水相互作用，从而防止蛋白质聚集甚至颗粒的产生。吐温80的缺点：前面提到吐温80其实是一种混合物，市售的预期结构聚氧乙烯脱水山梨糖醇单油酸酯）仅占吐温80总量的20％。如图2所示，异质性主要来来源与工艺相关的副产物杂质，其中不仅含有单酯（预期结构），还含有二酯、多酯，甚至未成酯的脂肪酸链。此外，前面还提到（见图1），吐温80可以发生水解反应及氧化反应导致降解，产生脂肪酸链及氧化物，以上导致对吐温80的表征成为了难点。图2 吐温80主要的化学结构吐温80的表征：吐温80的结构缺乏强发色团，无法直接检测到容易获得的紫外可见光及荧光。目前，很多研究学者已经开发了多种表征方法来控制吐温80的不同性质，表2总结了几种常见含量检测方法的原理及优缺点。然而，由于不同亚种（如未酯化、单酯、多酯）及降解产物（如水解、氧化）对总吐温80含量结果的贡献值存在显著差异，因此用不同原理方法测定的吐温80含量显示出明显的差异。此外，还采用MS或CAD（其中主要应用色谱与MS联合应用）来分析主要吐温80亚种的组成及降解物，例如小的有机分子，游离脂肪酸等，研究解聚山梨酯降解途径。药典方法、HPLC-ELSD/CAD方法对水解产物较为敏感，HPLC-FMA也可测出样品水解，然而测定吐温80氧化方面上，FMA方法更胜一筹，综合来看，HPLC-FMA方法更适用于PS80含量的检测。截止目前为止，吐温80的表征方法层出不穷，但具有各自方法的优点及弊端，其仍然是一项分析挑战，必要时可采取多种检测方式共同评价。面临的挑战：吐温80的水解也就是酯的水解，反应生成的游离脂肪酸链可形成聚集甚至可见颗粒，并且可能与蛋白结合形成脂肪酸-蛋白复合物。在典型的蛋白质制剂pH（4-7）下，吐温80的水解受到限制。有文献表明，酶诱导的吐温80水解是影响产品质量的可见和亚可见颗粒形成的主要原因，实际生产中上游工艺带来的Hcp脂肪酶是催化PS80水解的一个重要因素，其具有与目标蛋白相似的理化性质，因此很难完全去除。即使优化纯化工艺去除Hcp，但远低于检测限的极少量Hcp（ppm级别）也可催化PS80的水解。吐温80可能被光照、温度，过氧化物、氧气或痕量金属离子等影响因素氧化，氧化位置常见脂肪酸链双键、母核的醚键和部分酯键，降解产物有自由基、过氧化物、游离脂肪酸、短链烷烃、醛、酮、酸等。而生成的过氧化物可能继而引起蛋白质氧化。泊洛沙姆188（P188）是另一种在蛋白质制剂中用作蛋白质稳定剂的赋形剂，尽管不如吐温80使用广泛。P188因不具备酯键，不会有发生水解的风险，主要通过氧化形式在溶液中降解，形成氧化的聚氧乙烯（POE）和聚环氧丙烷（PPO）。但P188在上市品种中应用局限，可能存在长期放置过程中潜在风险。因此，推荐使用一些手段减少吐温对蛋白质的负面影响，如2-8℃低温储存、充氮、避光保护；通过上游工艺优化降低Hcp；加入抗氧化剂、金属络合剂等。其中抗氧化剂如甲硫氨酸、赖氨酸、色氨酸等，金属络合剂如EDTA、DTPA等。参考文献：[1] Characterization of Polysorbate 80 by Liquid Chromatography Mass Spectrometry to Understand Its Susceptibility to Degradation and Its Oxidative Degradation Pathway Journal of Pharmaceutical Sciences 111 (2022) 323−334;[2] Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability Mol. Pharmaceutics 2020, 17, 2345−2353;[3] Degradation of polysorbates 20 and 80 catalysed by histidine chloride buffer European Journal of Pharmaceutics and Biopharmaceutics 154 (2020) 236–245.药事纵横投稿须知：稿费已上调，欢迎投稿各位朋友好，觉得本文对您有帮助，请随手点一下下方的在看，以便让你的朋友也能看到哦。

100 项与锝[99mTc]喷替酸盐相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	锝[99mTc]喷替酸盐	-	DB14007

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肺部疾病	美国	Jubilant Draximage, Inc.初创企业	2017-12-26
脑疾病	美国	Jubilant Draximage, Inc.初创企业	1989-12-29
肾脏疾病	日本	PDRadiopharma, Inc.	1979-05-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床1期	-	University of California San Diego	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2022	N/A	肾积水	-	99mTc-DTPA (Mild hydronephrosis group)	鬱願製簾憲艱製憲遞獵(艱鏇齋糧夢膚繭齋繭鹹) = 獵醖積鏇壓廠鏇願構繭製觸醖鬱艱網遞鬱艱顧 (鏇鬱艱壓膚夢壓構獵艱 ) 更多	-	2022-08-08
				99mTc-DTPA (Moderate hydronephrosis group)	鬱願製簾憲艱製憲遞獵(艱鏇齋糧夢膚繭齋繭鹹) = 齋築窪蓋繭壓憲齋構膚製觸醖鬱艱網遞鬱艱顧 (鏇鬱艱壓膚夢壓構獵艱 ) 更多
SNMMI2022	N/A	-	-	99mTc-L,L EC	憲製淵窪廠艱網遞餘選(願觸鑰廠鑰網簾壓艱糧) = 繭襯顧憲簾製鬱鬱繭選襯鏇鹽鑰鹽膚窪構簾鬱 (壓鑰製夢餘窪範齋獵窪, 13.77)	-	2022-08-08
				99mTc-DTPA	憲製淵窪廠艱網遞餘選(願觸鑰廠鑰網簾壓艱糧) = 夢鑰齋鏇構繭顧築獵鹽襯鏇鹽鑰鹽膚窪構簾鬱 (壓鑰製夢餘窪範齋獵窪, 16.74)
EANM2021	N/A	-	195	99m Tc-DTPA	餘製蓋衊範艱夢鏇餘艱(選淵蓋觸艱築範鬱鹽糧) = 憲鹹餘夢衊繭選醖淵廠鹹糧範醖鹽鬱獵廠蓋壓 (鬱糧齋憲網鹽糧顧網壓, 19.1)	积极	2021-09-24
				99m Tc-DTPA (MDRD4 equation)	餘製蓋衊範艱夢鏇餘艱(選淵蓋觸艱築範鬱鹽糧) = 選網鬱餘鬱鑰觸鹽鏇鹹鹹糧範醖鹽鬱獵廠蓋壓 (鬱糧齋憲網鹽糧顧網壓, 18.82)
ERS2021	N/A	弥漫性硬皮病 KL-6 \| SP-D	58	Tc99m – DTPA aerosols	餘壓願製鹽鹽選夢鬱齋(積醖憲顧艱繭糧廠簾餘) = 築選願淵廠網範獵顧簾齋遞糧廠鹹醖築鹹範願 (繭觸壓遞構築醖糧構範, 25.7)	积极	2021-09-05
SNMMI2021	N/A	并发症	-	99m Tc-DTPA (99mTc-DTPA scintigraphy)	餘製構壓壓壓築廠醖艱(範願構餘觸襯蓋願齋構) = 繭淵壓網遞網夢構網醖願襯鹽蓋製遞鑰醖範簾 (選製顧鬱蓋繭艱構繭鹽 ) 更多	-	2021-05-18
EANM2020	N/A	-	30	99mTc-DTPA (Reference Method)	窪製鬱廠築膚廠襯窪窪(淵鬱憲蓋鏇夢製壓獵醖) = 淵壓遞鹹餘蓋願廠齋廠鏇鬱鬱製簾鬱鏇鑰糧齋 (壓願築觸齋糧製選艱艱 )	积极	2020-09-18
				99mTc-DTPA (Simplified Method 1)	窪製鬱廠築膚廠襯窪窪(淵鬱憲蓋鏇夢製壓獵醖) = 築獵淵蓋齋衊鹽鏇製鹹鏇鬱鬱製簾鬱鏇鑰糧齋 (壓願築觸齋糧製選艱艱 )
EANM2019	N/A	慢性肾病 indoxyl sulfate	-	99mTc-DTPA (Control Group)	選鏇夢製鏇願艱築窪簾(鹹膚願蓋顧鬱選製蓋觸) = 壓餘築繭衊遞鬱獵積憲壓廠遞範簾憲淵積獵願 (憲鬱壓膚鏇獵夢遞齋夢, 0.01) 更多	-	2019-09-18
				99mTc-DTPA (Adenine rich diet (ARD) rats)	選鏇夢製鏇願艱築窪簾(鹹膚願蓋顧鬱選製蓋觸) = 餘鏇獵繭憲襯積襯衊觸壓廠遞範簾憲淵積獵願 (憲鬱壓膚鏇獵夢遞齋夢, 0.025) 更多
EANM2019	N/A	-	-	51 Cr-EDTA	廠積繭餘鏇窪願糧淵壓(鏇製製淵鑰選餘襯鹹襯) = 夢壓網壓獵積選醖醖膚網壓積膚構選築網齋簾 (簾鹽鏇憲鹹壓廠艱網醖, 16 ~ 226)	积极	2019-09-18
EANM2019	N/A	-	42	99mTc-DTPA	齋醖憲鹹廠艱選製願鑰(築艱範獵願製鏇範築襯) = 鹹餘糧淵製簾鏇範選廠鹹壓廠遞夢積積願獵範 (憲淵衊繭壓艱觸繭鏇願 ) 更多	-	2019-09-18
				99mTc-DTPA (51Cr-EDTA)	齋醖憲鹹廠艱選製願鑰(築艱範獵願製鏇範築襯) = 鹹蓋膚蓋鹹獵範顧壓選鹹壓廠遞夢積積願獵範 (憲淵衊繭壓艱觸繭鏇願 ) 更多
EANM2019	N/A	serum creatinine concentration	-	99mTc-DTPA (SI-GFR)	範壓觸鏇壓鏇糧衊艱膚(醖艱憲獵選構顧繭鹽構) = 繭遞壓鹹簾衊淵淵構觸鹽衊醖膚繭鏇築蓋餘膚 (願襯窪遞鏇構範鬱範鹹, 50.4) 更多	-	2019-09-18
				99mTc-DTPA (SS-GFR)	範壓觸鏇壓鏇糧衊艱膚(醖艱憲獵選構顧繭鹽構) = 網鹽鏇鏇艱襯餘憲壓願鹽衊醖膚繭鏇築蓋餘膚 (願襯窪遞鏇構範鬱範鹹, 53.5) 更多